生物技术与制药领域的最新动态
Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights - Business Wire
WilmerHale Advises Thermo Fisher Scientific on $9 Billion Acquisition of Clario - WilmerHale
Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 Billion - The Wall Street Journal
Lonza to buy rapid microbial testing firm Redberry SAS - Fierce Biotech
Agilent Technologies’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
14-year-old Combines Origami and Physics to Engineer Foldable Structures for Disaster Relief Shelters; Wins $25,000 Top Award at Thermo Fisher Scientific Junior Innovators Challenge - GlobeNewswire
Thermo Fisher Scientific Enables Semiconductor Manufacturers to See the Unseen with Helios MX1 PFIB-SEM - Business Wire
Thermo Fisher nears $10 billion takeover of Clario, FT reports - Reuters
Bristol in Friendswood to break ground in coming months; Lonza plans renovation in Pearland - Community Impact | News
Lonza to Acquire Redberry SAS - Contract Pharma
Lonza to expand bioscience testing offering with the acquisition of Redberry - Drug Discovery News
Agilent Names Adam S. Elinoff as Chief Financial Officer - Business Wire
Agilent Technologies Names Adam S. Elinoff as CFO - Yahoo Finance
Thermo Fisher Scientific Showcases Enhanced Accelerator™ Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025 - Business Wire
Will 10x Genomics’ (TXG) AI Partnership Shift Its Long-Term Competitive Edge in Genomics? - Yahoo Finance
Illumina (ILMN): Assessing Valuation After Launch of 5-Base Sequencing and Constellation Platform Advances - Yahoo Finance
Roche Earnings: We’re Slightly Lowering Our 2025 Sales Forecast but Encouraged by Diverse Pipeline - Morningstar Canada
Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site - Investing.com
Earnings call transcript: Lonza Group Q3 2025 sees strong CDMO growth - Investing.com
Lonza's recently purchased Calif. biologics site plays key role in sales rebound - Fierce Pharma